Status:
RECRUITING
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC
Conditions:
All Tumor Types
Eligibility:
All Genders
12+ years
Brief Summary
SPECTA is a quality assured platform for collecting clinicopathologically annotated biological material, imaging data, operative images, environmental assessment, questionnaires as well as patient-rep...
Detailed Description
Patients are recruited in the platform for the research purpose of 5 downstream projects. For more information, please have a look at the "Groups and cohorts" section.
Eligibility Criteria
- Patients with pathologically confirmed selected tumor types (at site or centrally);
- Mandatory availability of adequate human biological material (HBM);
- Centrally performed confirmation of HBM adequacy in terms of quality and quantity for SPECTA downstream project requirements;
- Age ≥ 12 years;
- Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule;
- Written informed consent according to applicable legal and ethical requirements;
Key Trial Info
Start Date :
May 3 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2031
Estimated Enrollment :
4975 Patients enrolled
Trial Details
Trial ID
NCT02834884
Start Date
May 3 2017
End Date
October 1 2031
Last Update
April 17 2026
Active Locations (134)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University Vienna - General Hospital AKH
Vienna, Austria, 1090
2
Onze Lieve Vrouw Ziekenhuis
Aalst, Belgium, 9300
3
ZAS Middelheim
Antwerp, Belgium, 2020
4
Hopitaux Universitaires - Institut Jules Bordet
Brussels, Belgium, 1000